These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19571029)

  • 1. Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. and other yeasts.
    Espinel-Ingroff A; Canton E; Peman J; Rinaldi MG; Fothergill AW
    J Clin Microbiol; 2009 Sep; 47(9):2766-71. PubMed ID: 19571029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2011 Feb; 49(2):630-7. PubMed ID: 21159940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.
    Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Fothergill A; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
    J Clin Microbiol; 2005 Sep; 43(9):4535-40. PubMed ID: 16145103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
    Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Diekema DJ
    J Clin Microbiol; 2007 Jan; 45(1):70-5. PubMed ID: 17079501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
    J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.
    Pfaller MA; Boyken LB; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2011 Apr; 49(4):1274-9. PubMed ID: 21289155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    J Clin Microbiol; 2007 Nov; 45(11):3522-8. PubMed ID: 17913927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media.
    Pfaller MA; Messer SA; Houston A; Mills K; Bolmstrom A; Jones RN
    J Clin Microbiol; 2000 Oct; 38(10):3715-7. PubMed ID: 11015389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal susceptibility of 205 Candida spp. isolated primarily during invasive Candidiasis and comparison of the Vitek 2 system with the CLSI broth microdilution and Etest methods.
    Bourgeois N; Dehandschoewercker L; Bertout S; Bousquet PJ; Rispail P; Lachaud L
    J Clin Microbiol; 2010 Jan; 48(1):154-61. PubMed ID: 19889902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two microdilution methods for testing susceptibility of Candida spp. to voriconazole.
    Linares MJ; Charriel G; Solís F; Casal M
    J Clin Microbiol; 2004 Feb; 42(2):899-902. PubMed ID: 14766884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
    Fleck R; Dietz A; Hof H
    J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood.
    Maxwell MJ; Messer SA; Hollis RJ; Boyken L; Tendolkar S; Diekema DJ; Pfaller MA
    J Clin Microbiol; 2003 Mar; 41(3):1087-90. PubMed ID: 12624034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of four reading methods of broth microdilution based on the clinical and laboratory standards institute M27-A3 method for Candida spp.
    Morishige H; Mano Y; Oguri T; Furuya N
    Jpn J Antibiot; 2012 Oct; 65(5):335-47. PubMed ID: 23383435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the VITEK 2 system (AST-YSO1 cards) for antifungal susceptibility testing against different Candida species].
    Ochiuzzi ME; Arechavala A; Guelfand L; Maldonado I; Soloaga R;
    Rev Argent Microbiol; 2014; 46(2):111-8. PubMed ID: 25011594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents.
    Alexander BD; Byrne TC; Smith KL; Hanson KE; Anstrom KJ; Perfect JR; Reller LB
    J Clin Microbiol; 2007 Mar; 45(3):698-706. PubMed ID: 17202279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.
    Pfaller MA; Boyken L; Messer SA; Tendolkar S; Hollis RJ; Diekema DJ
    J Clin Microbiol; 2005 Oct; 43(10):5208-13. PubMed ID: 16207985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.